 Mary Bessesen
Concepts (203)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Respiratory Protective Devices | 6 | 2021 | 13 | 2.880 |
Why?
| | Health Personnel | 10 | 2021 | 520 | 1.690 |
Why?
| | Infection Control | 7 | 2019 | 137 | 1.670 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 5 | 2016 | 175 | 1.650 |
Why?
| | Staphylococcal Infections | 5 | 2016 | 323 | 1.450 |
Why?
| | Respiratory Tract Infections | 5 | 2021 | 292 | 1.400 |
Why?
| | Bacteremia | 5 | 2020 | 159 | 1.250 |
Why?
| | Equipment Reuse | 2 | 2015 | 10 | 1.160 |
Why?
| | Cross Infection | 5 | 2016 | 203 | 1.160 |
Why?
| | Disinfection | 2 | 2015 | 82 | 1.080 |
Why?
| | Masks | 4 | 2021 | 32 | 1.040 |
Why?
| | Veterans | 3 | 2020 | 973 | 0.880 |
Why?
| | Carrier State | 3 | 2016 | 55 | 0.870 |
Why?
| | Rifampin | 1 | 2020 | 75 | 0.760 |
Why?
| | Diabetic Foot | 1 | 2020 | 57 | 0.750 |
Why?
| | Osteomyelitis | 1 | 2020 | 110 | 0.700 |
Why?
| | Amputation | 1 | 2020 | 188 | 0.680 |
Why?
| | Influenza, Human | 5 | 2022 | 519 | 0.680 |
Why?
| | Nose | 2 | 2015 | 53 | 0.670 |
Why?
| | Pre-Exposure Prophylaxis | 1 | 2018 | 164 | 0.590 |
Why?
| | Anti-HIV Agents | 2 | 2018 | 694 | 0.550 |
Why?
| | HIV Infections | 3 | 2018 | 2514 | 0.490 |
Why?
| | Medication Adherence | 1 | 2018 | 574 | 0.470 |
Why?
| | AIDS-Related Opportunistic Infections | 4 | 1999 | 119 | 0.460 |
Why?
| | Occupational Exposure | 2 | 2019 | 312 | 0.430 |
Why?
| | Polymers | 1 | 2015 | 479 | 0.420 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2012 | 277 | 0.410 |
Why?
| | Osteoporosis | 1 | 2012 | 201 | 0.400 |
Why?
| | Catheters, Indwelling | 1 | 2010 | 86 | 0.390 |
Why?
| | Catheter-Related Infections | 1 | 2010 | 59 | 0.390 |
Why?
| | Microbiota | 1 | 2015 | 508 | 0.380 |
Why?
| | Catheterization, Central Venous | 1 | 2010 | 83 | 0.380 |
Why?
| | Delivery of Health Care | 6 | 2022 | 744 | 0.380 |
Why?
| | Escherichia coli Infections | 2 | 2013 | 125 | 0.340 |
Why?
| | Influenza Vaccines | 2 | 2022 | 473 | 0.310 |
Why?
| | Elastomers | 2 | 2015 | 27 | 0.280 |
Why?
| | Humans | 35 | 2022 | 115152 | 0.280 |
Why?
| | Acquired Immunodeficiency Syndrome | 2 | 1999 | 218 | 0.270 |
Why?
| | Mycobacterium avium | 1 | 2004 | 19 | 0.260 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2004 | 19 | 0.260 |
Why?
| | Molecular Typing | 1 | 2013 | 18 | 0.260 |
Why?
| | Mycobacterium avium-intracellulare Infection | 2 | 2004 | 60 | 0.250 |
Why?
| | Peritonitis | 1 | 2004 | 79 | 0.250 |
Why?
| | Polymerase Chain Reaction | 3 | 2015 | 1048 | 0.250 |
Why?
| | Drug Resistance, Multiple, Bacterial | 1 | 2013 | 64 | 0.240 |
Why?
| | Feasibility Studies | 2 | 2015 | 759 | 0.230 |
Why?
| | Coronavirus OC43, Human | 1 | 2021 | 4 | 0.230 |
Why?
| | Orthomyxoviridae Infections | 1 | 2022 | 51 | 0.220 |
Why?
| | Escherichia coli | 2 | 2013 | 798 | 0.210 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2022 | 144 | 0.200 |
Why?
| | Male | 16 | 2020 | 60974 | 0.200 |
Why?
| | Viruses | 1 | 2021 | 93 | 0.200 |
Why?
| | Anti-Bacterial Agents | 4 | 2020 | 1377 | 0.190 |
Why?
| | Infectious Disease Transmission, Patient-to-Professional | 1 | 2019 | 21 | 0.190 |
Why?
| | Placebos | 1 | 2020 | 212 | 0.190 |
Why?
| | Hepatitis B, Chronic | 1 | 1999 | 17 | 0.190 |
Why?
| | Staphylococcus aureus | 2 | 2015 | 380 | 0.190 |
Why?
| | Attitude | 1 | 2021 | 237 | 0.190 |
Why?
| | Lamivudine | 1 | 1999 | 56 | 0.190 |
Why?
| | Foot | 1 | 2020 | 120 | 0.180 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 91 | 0.180 |
Why?
| | Outpatients | 1 | 2021 | 269 | 0.180 |
Why?
| | Financing, Government | 1 | 1999 | 51 | 0.180 |
Why?
| | Mandatory Programs | 1 | 2018 | 17 | 0.170 |
Why?
| | Nasal Cavity | 2 | 2016 | 50 | 0.170 |
Why?
| | Secondary Prevention | 1 | 2020 | 256 | 0.170 |
Why?
| | Middle Aged | 9 | 2020 | 28958 | 0.170 |
Why?
| | Female | 12 | 2020 | 63300 | 0.170 |
Why?
| | Adult | 11 | 2020 | 32204 | 0.170 |
Why?
| | Sterilization | 1 | 2017 | 17 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2020 | 11727 | 0.150 |
Why?
| | Antibiosis | 1 | 2015 | 7 | 0.150 |
Why?
| | Streptococcus mitis | 1 | 2015 | 8 | 0.150 |
Why?
| | Lactobacillus | 1 | 2015 | 25 | 0.150 |
Why?
| | Vaccination | 3 | 2021 | 1094 | 0.150 |
Why?
| | Nasal Mucosa | 1 | 2016 | 95 | 0.140 |
Why?
| | Sulfadoxine | 1 | 1995 | 4 | 0.140 |
Why?
| | Pyrimethamine | 1 | 1995 | 2 | 0.140 |
Why?
| | Catalase | 1 | 2015 | 135 | 0.140 |
Why?
| | Tertiary Care Centers | 1 | 2016 | 129 | 0.140 |
Why?
| | Double-Blind Method | 1 | 2020 | 1682 | 0.140 |
Why?
| | Pneumonia, Pneumocystis | 1 | 1995 | 35 | 0.140 |
Why?
| | Disease Transmission, Infectious | 1 | 2015 | 64 | 0.140 |
Why?
| | Equipment Contamination | 1 | 2015 | 51 | 0.140 |
Why?
| | Treatment Outcome | 4 | 2020 | 9219 | 0.140 |
Why?
| | Sequence Analysis, DNA | 2 | 2015 | 735 | 0.140 |
Why?
| | Cost-Benefit Analysis | 1 | 2017 | 556 | 0.130 |
Why?
| | Occupational Diseases | 1 | 2016 | 146 | 0.130 |
Why?
| | Efficiency, Organizational | 2 | 2018 | 137 | 0.130 |
Why?
| | Reference Standards | 1 | 2015 | 195 | 0.130 |
Why?
| | Virus Diseases | 1 | 2016 | 190 | 0.130 |
Why?
| | Risk Factors | 4 | 2021 | 9105 | 0.130 |
Why?
| | Task Performance and Analysis | 1 | 2015 | 186 | 0.130 |
Why?
| | Medical Errors | 1 | 2015 | 103 | 0.130 |
Why?
| | Prospective Studies | 3 | 2020 | 6324 | 0.130 |
Why?
| | Aged | 3 | 2020 | 20309 | 0.130 |
Why?
| | HIV-1 | 1 | 1999 | 790 | 0.120 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2015 | 476 | 0.120 |
Why?
| | Mycobacterium Infections | 1 | 1993 | 64 | 0.120 |
Why?
| | Cohort Studies | 3 | 2020 | 5026 | 0.120 |
Why?
| | Follow-Up Studies | 2 | 2018 | 4959 | 0.120 |
Why?
| | Bone Density Conservation Agents | 1 | 2012 | 62 | 0.120 |
Why?
| | Osteoporotic Fractures | 1 | 2012 | 46 | 0.110 |
Why?
| | Prevalence | 2 | 2013 | 2403 | 0.110 |
Why?
| | United States Department of Veterans Affairs | 1 | 2015 | 526 | 0.110 |
Why?
| | Risk Assessment | 2 | 2016 | 3215 | 0.110 |
Why?
| | Incidence | 2 | 2019 | 2456 | 0.100 |
Why?
| | Ergonomics | 1 | 2010 | 21 | 0.100 |
Why?
| | Listeria monocytogenes | 1 | 1990 | 94 | 0.100 |
Why?
| | Metagenome | 1 | 2010 | 111 | 0.090 |
Why?
| | United States | 4 | 2018 | 12598 | 0.090 |
Why?
| | Hospitalization | 2 | 2015 | 1727 | 0.090 |
Why?
| | Molecular Epidemiology | 2 | 2013 | 59 | 0.090 |
Why?
| | Aged, 80 and over | 1 | 2020 | 6845 | 0.080 |
Why?
| | Drug Therapy, Combination | 2 | 2004 | 1007 | 0.080 |
Why?
| | Cytosine | 1 | 2005 | 49 | 0.070 |
Why?
| | Organophosphonates | 1 | 2005 | 97 | 0.070 |
Why?
| | Herpes Simplex | 1 | 2005 | 100 | 0.070 |
Why?
| | Immunocompetence | 1 | 2004 | 46 | 0.070 |
Why?
| | Ambulatory Care | 2 | 2019 | 463 | 0.070 |
Why?
| | Adolescent | 3 | 2020 | 18716 | 0.060 |
Why?
| | Young Adult | 1 | 2020 | 11032 | 0.060 |
Why?
| | Fluoroquinolones | 1 | 2013 | 42 | 0.060 |
Why?
| | beta-Lactams | 1 | 2013 | 23 | 0.060 |
Why?
| | Inpatients | 2 | 2020 | 353 | 0.060 |
Why?
| | Infusions, Intravenous | 1 | 2004 | 406 | 0.060 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2022 | 39 | 0.060 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2022 | 32 | 0.060 |
Why?
| | Virulence Factors | 1 | 2013 | 139 | 0.060 |
Why?
| | Escherichia coli Proteins | 1 | 2013 | 171 | 0.060 |
Why?
| | Hepatitis B e Antigens | 1 | 1999 | 2 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2005 | 648 | 0.050 |
Why?
| | Drug Resistance | 1 | 1999 | 185 | 0.040 |
Why?
| | Program Evaluation | 2 | 2015 | 877 | 0.040 |
Why?
| | Antibodies, Viral | 1 | 2022 | 543 | 0.040 |
Why?
| | Treatment Failure | 1 | 1999 | 336 | 0.040 |
Why?
| | Absenteeism | 1 | 2018 | 39 | 0.040 |
Why?
| | Genotype | 1 | 2013 | 1854 | 0.040 |
Why?
| | Surgical Instruments | 1 | 2017 | 43 | 0.040 |
Why?
| | Operating Rooms | 1 | 2017 | 82 | 0.040 |
Why?
| | Hospital Costs | 1 | 2017 | 126 | 0.040 |
Why?
| | Recurrence | 1 | 1999 | 990 | 0.040 |
Why?
| | Hand Hygiene | 1 | 2015 | 6 | 0.040 |
Why?
| | Immunization Programs | 1 | 2018 | 208 | 0.040 |
Why?
| | Pentamidine | 1 | 1995 | 4 | 0.040 |
Why?
| | Seasons | 1 | 2018 | 438 | 0.040 |
Why?
| | Communicable Diseases, Emerging | 1 | 2015 | 30 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2015 | 42 | 0.040 |
Why?
| | Severity of Illness Index | 1 | 2004 | 2853 | 0.040 |
Why?
| | Zidovudine | 1 | 1995 | 80 | 0.030 |
Why?
| | Health Policy | 1 | 2018 | 361 | 0.030 |
Why?
| | Workplace | 1 | 2016 | 248 | 0.030 |
Why?
| | Administration, Inhalation | 1 | 1995 | 673 | 0.030 |
Why?
| | Occupational Health | 1 | 2015 | 211 | 0.030 |
Why?
| | Global Health | 1 | 2015 | 346 | 0.030 |
Why?
| | Digestive System | 1 | 1991 | 26 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2015 | 394 | 0.030 |
Why?
| | Listeria | 1 | 1990 | 4 | 0.030 |
Why?
| | Patients' Rooms | 1 | 2010 | 9 | 0.030 |
Why?
| | Time and Motion Studies | 1 | 2010 | 30 | 0.030 |
Why?
| | Manikins | 1 | 2010 | 28 | 0.030 |
Why?
| | Facility Design and Construction | 1 | 2010 | 16 | 0.030 |
Why?
| | Hand Disinfection | 1 | 2010 | 16 | 0.030 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 1995 | 280 | 0.030 |
Why?
| | Diarrhea | 1 | 1991 | 178 | 0.030 |
Why?
| | Bacterial Typing Techniques | 1 | 2010 | 39 | 0.030 |
Why?
| | Evaluation Studies as Topic | 1 | 1990 | 219 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2010 | 85 | 0.030 |
Why?
| | DNA, Ribosomal | 1 | 2010 | 84 | 0.030 |
Why?
| | Quality Control | 1 | 2010 | 166 | 0.020 |
Why?
| | Health | 1 | 2010 | 74 | 0.020 |
Why?
| | Feedback | 1 | 2010 | 147 | 0.020 |
Why?
| | Staphylococcus epidermidis | 1 | 2010 | 70 | 0.020 |
Why?
| | Checklist | 1 | 2010 | 75 | 0.020 |
Why?
| | Workload | 1 | 2010 | 136 | 0.020 |
Why?
| | Problem Solving | 1 | 2010 | 161 | 0.020 |
Why?
| | Species Specificity | 1 | 1990 | 619 | 0.020 |
Why?
| | Time Factors | 2 | 2010 | 7041 | 0.020 |
Why?
| | Equipment Design | 1 | 2010 | 533 | 0.020 |
Why?
| | Cues | 1 | 2010 | 304 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2010 | 287 | 0.020 |
Why?
| | Community-Acquired Infections | 1 | 2009 | 134 | 0.020 |
Why?
| | DNA, Bacterial | 1 | 2009 | 301 | 0.020 |
Why?
| | Attention | 1 | 2010 | 465 | 0.020 |
Why?
| | Biodiversity | 1 | 2010 | 350 | 0.020 |
Why?
| | Intensive Care Units | 1 | 2010 | 599 | 0.020 |
Why?
| | Motivation | 1 | 2010 | 516 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 1990 | 1922 | 0.020 |
Why?
| | Simplexvirus | 1 | 2005 | 94 | 0.020 |
Why?
| | Child | 2 | 2021 | 17939 | 0.020 |
Why?
| | Drug Resistance, Viral | 1 | 2005 | 101 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2010 | 3014 | 0.020 |
Why?
| | Bacteria | 1 | 1990 | 661 | 0.020 |
Why?
| | Bone Marrow Transplantation | 1 | 2005 | 268 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2010 | 2676 | 0.010 |
Why?
| | Life Tables | 1 | 1995 | 27 | 0.010 |
Why?
| | Mycobacterium avium Complex | 1 | 1995 | 87 | 0.010 |
Why?
| | Australia | 1 | 1995 | 228 | 0.010 |
Why?
| | CD4 Lymphocyte Count | 1 | 1995 | 290 | 0.010 |
Why?
| | Europe | 1 | 1995 | 334 | 0.010 |
Why?
| | North America | 1 | 1995 | 273 | 0.010 |
Why?
| | Survival Rate | 1 | 1995 | 1862 | 0.010 |
Why?
| | Case-Control Studies | 1 | 1995 | 3261 | 0.010 |
Why?
|
|
Bessesen's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|